Anzeige
Mehr »
Login
Mittwoch, 15.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Das 13-Millionen-Unternehmen mit einer Monster-Entdeckung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A400BU | ISIN: KYG1180K1168 | Ticker-Symbol:
NASDAQ
13.01.25
21:59 Uhr
0,540 US-Dollar
-0,011
-2,00 %
Branche
Medien
Aktienmarkt
JAPAN
1-Jahres-Chart
BLOOMZ INC Chart 1 Jahr
5-Tage-Chart
BLOOMZ INC 5-Tage-Chart
ACCESSWIRE
341 Leser
Artikel bewerten:
(2)

BloomZ Announces Strategic Business Alliance with CrossVision to Create Joint Entertainment Offerings

Finanznachrichten News

TOKYO, JAPAN / ACCESSWIRE / September 5, 2024 / BloomZ Inc. ("BloomZ" or the "Company"), a Japanese audio production and voice actor management company, announced today that on September 4, 2024, it entered into a business alliance agreement with CrossVision Inc. ("CrossVision"), a Japanese digital entertainment company specializing in Web 3.0 technology, to create joint entertainment offerings.

Through cooperation with CrossVision, BloomZ plans to combine its expertise and network in the animation and VTuber industries with CrossVision's advanced Web 3.0 technology. Together, BloomZ and CrossVision aim to enhance fan engagement with blockchain technology, and live events in the metaverse. By integrating CrossVision's technology into BloomZ's production processes, BloomZ expects to develop new digital content, offering interactive and personalized experiences. This collaboration is expected to allow customers to own and trade digital items, directly reflecting their contributions to the content, and create virtual communities where they can connect and experience live events in real-time.

"I am pleased to announce our strategic business alliance with CrossVision, which we believe is a significant milestone in diversifying and innovating the revenue streams in our animation production and VTuber management business," said BloomZ CEO, Kazusa Aranami. "In recent years, blockchain technology has emerged as a new source of revenue within the digital entertainment space, gradually gaining market acceptance. Finding innovative ways to connect our customers with our animation projects and affiliated VTubers has always been a key focus for us. Through this cooperation with CrossVision, we aim to use Web 3.0 technology to create new and engaging experiences, allowing our customers to interact with their favorite animation projects, VTubers, and each other. We believe the integration of blockchain technology and digital assets will open new revenue streams, further strengthening our financial growth and enhancing shareholder value. We look forward to working with CrossVision to incorporate their technologies with our business."

About BloomZ Inc.
BloomZ is a Cayman Islands holding company with an operating subsidiary, Kabushiki Kaisha BloomZ ("BloomZ Japan"), in Japan. BloomZ Japan is a Japanese audio producing and voice actor and VTuber managing company. BloomZ Japan has experienced staff who have worked on audio production for animations and video games for more than 10 years. BloomZ Japan also manages, cultivates and promotes voice actors and VTubers.

Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release.

BloomZ Investor Contact
John Yi and Steven Shinmachi
Gateway Group, Inc.
949-574-3860
Email: bloomz@gateway-grp.com

SOURCE: BloomZ



View the original press release on accesswire.com

© 2024 ACCESSWIRE
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.